Response and survival outcomes by response to prior AML treatment(s) for patients with R/R AML who received enasidenib 100, mg/day
. | Refractory to intensive chemotherapy (n = 40) . | Refractory to lower-intensity therapy (n = 44)† . | Relapsed following any prior AML therapy (n = 130) . |
---|---|---|---|
ORR, n (%) [95% CI]* | 15 (37.5) [22.7-54.2] | 19 (43.2) [28.4-59.0] | 49 (37.7) [29.4-46.6] |
CR, n (%) | 4 (10.0) | 12 (27.3) | 26 (20.0) |
CRi/CRp, n (%) | 4 (10.0) | 2 (4.5) | 14 (10.8) |
OS, median (95% CI), mo | 12.4 (8.2-22.9) | 8.0 (5.6-11.7) | 8.1 (7.0-9.3) |
. | Refractory to intensive chemotherapy (n = 40) . | Refractory to lower-intensity therapy (n = 44)† . | Relapsed following any prior AML therapy (n = 130) . |
---|---|---|---|
ORR, n (%) [95% CI]* | 15 (37.5) [22.7-54.2] | 19 (43.2) [28.4-59.0] | 49 (37.7) [29.4-46.6] |
CR, n (%) | 4 (10.0) | 12 (27.3) | 26 (20.0) |
CRi/CRp, n (%) | 4 (10.0) | 2 (4.5) | 14 (10.8) |
OS, median (95% CI), mo | 12.4 (8.2-22.9) | 8.0 (5.6-11.7) | 8.1 (7.0-9.3) |